Search research articles
Contact Us
Filters
Showing results (241-250 of 910) with videos related to
Page
of 91
Sort By:
The American Journal of Medicine
|
January 13, 2004
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
Abdallah G Rebeiz, Matthew T Roe, John H Alexander, et al.
American Journal of Epidemiology
|
March 7, 2015
Roger et al. respond to "future of population studies"
Véronique L Roger, Eric Boerwinkle, James D Crapo, et al.
Clinical Trials (London, England)
|
March 19, 2019
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program
Jay S Shavadia, Abhinav Sharma, Xiangqiong Gu, et al.
European Heart Journal
|
March 28, 2024
Cardiac implantable electronic devices and bloodstream infections: management and outcomes
Tardu Özkartal, Andrea Demarchi, Giulio Conte, et al.
Journal of Medical Systems
|
May 28, 2010
Economic assessment of thrombocytopenia: CATCH Registry
Eric L Eisenstein, Emily F Honeycutt, Kevin J Anstrom, et al.
European Heart Journal
|
March 6, 2008
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy
Michael A McDonald, Yuling Fu, Uwe Zeymer, et al.
American Heart Journal
|
April 25, 2007
Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting
E Marc Jolicoeur, Christopher B Granger, John L Fakunding, et al.
American Heart Journal
|
June 2, 2007
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)
David Brieger, Frans Van de Werf, Alvaro Avezum, et al.
Journal of the American College of Cardiology
|
May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
Lars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Circulation. Cardiovascular Quality and Outcomes
|
March 18, 2010
Cognitive function and anticoagulation control in patients with atrial fibrillation
Greg C Flaker, Janice Pogue, Salim Yusuf, et al.
Page
of 91
Search research articles
Search
Showing results (241-250 of 910) with videos related to
Sort By:
Page
of 91
The American Journal of Medicine
|
January 13, 2004
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
Abdallah G Rebeiz, Matthew T Roe, John H Alexander, et al.
American Journal of Epidemiology
|
March 7, 2015
Roger et al. respond to "future of population studies"
Véronique L Roger, Eric Boerwinkle, James D Crapo, et al.
Clinical Trials (London, England)
|
March 19, 2019
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program
Jay S Shavadia, Abhinav Sharma, Xiangqiong Gu, et al.
European Heart Journal
|
March 28, 2024
Cardiac implantable electronic devices and bloodstream infections: management and outcomes
Tardu Özkartal, Andrea Demarchi, Giulio Conte, et al.
Journal of Medical Systems
|
May 28, 2010
Economic assessment of thrombocytopenia: CATCH Registry
Eric L Eisenstein, Emily F Honeycutt, Kevin J Anstrom, et al.
European Heart Journal
|
March 6, 2008
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy
Michael A McDonald, Yuling Fu, Uwe Zeymer, et al.
American Heart Journal
|
April 25, 2007
Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting
E Marc Jolicoeur, Christopher B Granger, John L Fakunding, et al.
American Heart Journal
|
June 2, 2007
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)
David Brieger, Frans Van de Werf, Alvaro Avezum, et al.
Journal of the American College of Cardiology
|
May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
Lars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Circulation. Cardiovascular Quality and Outcomes
|
March 18, 2010
Cognitive function and anticoagulation control in patients with atrial fibrillation
Greg C Flaker, Janice Pogue, Salim Yusuf, et al.
Page
of 91